Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
152.15 -0.72 (-0.47%) 01/31/25 [NYSE]
152.00 x 100 152.40 x 500
Realtime by (Cboe BZX)
152.00 x 100 152.40 x 500
Realtime 152.06 -0.09 (-0.06%) 01/31/25
Quote Overview for Fri, Jan 31st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
152.06
Day High
153.18
Open 152.62
Previous Close 152.87 152.87
Volume 8,458,700 8,458,700
Avg Vol 9,641,460 9,641,460
Stochastic %K 85.34% 85.34%
Weighted Alpha -2.82 -2.82
5-Day Change +5.33 (+3.63%) +5.33 (+3.63%)
52-Week Range 140.68 - 168.85 140.68 - 168.85
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 366,319,840
  • Shares Outstanding, K 2,407,623
  • Annual Sales, $ 88,821 M
  • Annual Income, $ 14,066 M
  • EBIT $ 14,297 M
  • EBITDA $ 21,783 M
  • 60-Month Beta 0.51
  • Price/Sales 4.14
  • Price/Cash Flow 11.19
  • Price/Book 5.25

Options Overview Details

View History
  • Implied Volatility 15.49% ( +1.14%)
  • Historical Volatility 20.74%
  • IV Percentile 32%
  • IV Rank 26.74%
  • IV High 23.61% on 01/10/25
  • IV Low 12.53% on 05/09/24
  • Put/Call Vol Ratio 0.38
  • Today's Volume 26,000
  • Volume Avg (30-Day) 47,949
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 416,367
  • Open Int (30-Day) 399,840

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.60
  • Number of Estimates 7
  • High Estimate 2.67
  • Low Estimate 2.51
  • Prior Year 2.71
  • Growth Rate Est. (year over year) -4.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
140.68 +8.15%
on 01/10/25
Period Open: 144.62
154.14 -1.29%
on 01/30/25
+7.53 (+5.21%)
since 12/31/24
3-Month
140.68 +8.15%
on 01/10/25
Period Open: 159.86
161.06 -5.53%
on 11/01/24
-7.71 (-4.82%)
since 10/31/24
52-Week
140.68 +8.15%
on 01/10/25
Period Open: 158.77
168.85 -9.89%
on 09/04/24
-6.62 (-4.17%)
since 01/30/24

Most Recent Stories

More News
Is Johnson & Johnson Stock a Buy?

Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would be a no-brainer buy. However, Johnson & Johnson...

JNJ : 152.15 (-0.47%)
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?

Johnson & Johnson (NYSE: JNJ) has a diverse healthcare business, and investors often look to it as a safe dividend stock to invest in for the long term. One area where it has been lacking, however, is...

JNJ : 152.15 (-0.47%)
Did Johnson & Johnson Just Give Investors 23 Billion Reasons to Buy Its Stock?

Johnson & Johnson (NYSE: JNJ) didn't have an exceptional 2024; in fact, it was one of the worst-performing stocks on the vaunted, 30-company Dow Jones Industrial Average that year.

JNJ : 152.15 (-0.47%)
KVUE : 21.29 (-1.98%)
AbbVie Beats on Q4 Earnings & Sales, Raises Sales View for Key Drugs

AbbVie Inc. ABBV reported fourth-quarter 2024 adjusted earnings of $2.16 per share, which beat the Zacks Consensus Estimate of $2.13. The reported earnings also exceeded the company’s guidance of $2.06-$2.10...

JNJ : 152.15 (-0.47%)
ABBV : 183.90 (+4.70%)
RHHBY : 39.2500 (-1.48%)
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of the disease.This...

JNJ : 152.15 (-0.47%)
MRK : 98.82 (-0.13%)
UTHR : 351.17 (-0.32%)
Johnson & Johnson (NYSE:JNJ) Posts Q4 Sales In Line With Estimates

Johnson & Johnson (NYSE:JNJ) Posts Q4 Sales In Line With Estimates

JNJ : 152.15 (-0.47%)
TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the Zacks Consensus Estimate of 70 cents. Adjusted earnings declined 29% year over...

JNJ : 152.15 (-0.47%)
TEVA : 17.73 (-0.62%)
ABBV : 183.90 (+4.70%)
SNY : 54.34 (+0.35%)
2 Dividend Kings You Should Snap Up Immediately

Recent earnings from these dividend-paying companies reflects their stability.

NVDA : 120.07 (-3.67%)
$SPX : 6,040.53 (-0.50%)
JNJ : 152.15 (-0.47%)
PG : 165.99 (-0.85%)
KVUE : 21.29 (-1.98%)
AbbVie Q4 Earnings Loom: Buy or Sell ABBV Stock Ahead of Results?

AbbVie ABBV is set to report fourth-quarter and full-year 2024 earnings on Jan. 31, before the opening bell. The Zacks Consensus Estimate for the quarter’s sales and earnings is pegged at $14.92 billion...

JNJ : 152.15 (-0.47%)
ABBV : 183.90 (+4.70%)
RHHBY : 39.2500 (-1.48%)
3 Stocks Upgraded by Bank of America – Here's Why They're Bullish

Bank of America analysts have recently shifted their views on these three stocks, leaving investors with a few points to consider.

NFLX : 976.76 (+0.36%)
V : 341.80 (-0.36%)
JNJ : 152.15 (-0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 153.99
2nd Resistance Point 153.59
1st Resistance Point 152.87
Last Price 152.15
1st Support Level 151.74
2nd Support Level 151.34
3rd Support Level 150.62

See More

52-Week High 168.85
Fibonacci 61.8% 158.09
Fibonacci 50% 154.76
Last Price 152.15
Fibonacci 38.2% 151.44
52-Week Low 140.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Exclusive Barchart Webinar: Unlock the Power of High-Accuracy Option Trading